Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
LDL
Biotech
Lilly preps gene editor for ph. 2 after strong cholesterol cuts
A one-time infusion of a Verve base editor led to a sustained 62% drop in cholesterol, clearing the bar set by approved PCSK9 inhibitors.
Darren Incorvaia
May 25, 2026 8:45am
Merck's PCSK9 drug mounts injectable-like cholesterol reductions
Nov 10, 2025 10:59am
NewAmsterdam shares more data on lipid-lowering Amgen castoff
Apr 9, 2024 5:30am
NewAmsterdam's Amgen castoff cuts LDL cholesterol in phase 2
Jan 17, 2023 9:15am
